199 research outputs found
Quadratic fermionic interactions yield effective Hamiltonians for adiabatic quantum computing
Polynomially-large ground-state energy gaps are rare in many-body quantum
systems, but useful for adiabatic quantum computing. We show analytically that
the gap is generically polynomially-large for quadratic fermionic Hamiltonians.
We then prove that adiabatic quantum computing can realize the ground states of
Hamiltonians with certain random interactions, as well as the ground states of
one, two, and three-dimensional fermionic interaction lattices, in polynomial
time. Finally, we use the Jordan-Wigner transformation and a related
transformation for spin-3/2 particles to show that our results can be restated
using spin operators in a surprisingly simple manner. A direct consequence is
that the one-dimensional cluster state can be found in polynomial time using
adiabatic quantum computing.Comment: 14 page
SUSY parameter determination at the LHC using cross sections and kinematic edges
We study the determination of supersymmetric parameters at the LHC from a
global fit including cross sections and edges of kinematic distributions. For
illustration, we focus on a minimal supergravity scenario and discuss how well
it can be constrained at the LHC operating at 7 and 14 TeV collision energy,
respectively. We find that the inclusion of cross sections greatly improves the
accuracy of the SUSY parameter determination, and allows to reliably extract
model parameters even in the initial phase of LHC data taking with 7 TeV
collision energy and 1/fb integrated luminosity. Moreover, cross section
information may be essential to study more general scenarios, such as those
with non-universal gaugino masses, and distinguish them from minimal,
universal, models.Comment: 22 pages, 8 figure
Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study
Background & AimsPatients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection. Antiviral treatment before transplantation can prevent HCV recurrence, but existing interferon-based regimens are poorly tolerated and are either ineffective or contraindicated in most patients. We performed a trial to determine whether sofosbuvir and ribavirin treatment before liver transplantation could prevent HCV recurrence afterward.MethodsIn a phase 2, open-label study, 61 patients with HCV of any genotype and cirrhosis (Child–Turcotte–Pugh score, ≤7) who were on waitlists for liver transplantation for hepatocellular carcinoma, received up to 48 weeks of sofosbuvir (400 mg) and ribavirin before liver transplantation. The primary end point was the proportion of patients with HCV-RNA levels less than 25 IU/mL at 12 weeks after transplantation among patients with this HCV-RNA level at their last measurement before transplantation.ResultsSixty-one patients received sofosbuvir and ribavirin, and 46 received transplanted livers. The per-protocol efficacy population consisted of 43 patients who had HCV-RNA level less than 25 IU/mL at the time of transplantation. Of these 43 patients, 30 (70%) had a post-transplantation virologic response at 12 weeks, 10 (23%) had recurrent infection, and 3 (7%) died (2 from nonfunction of the primary graft and 1 from complications of hepatic artery thrombosis). Of all 61 patients given sofosbuvir and ribavirin, 49% had a post-transplantation virologic response. Recurrence was related inversely to the number of consecutive days of undetectable HCV RNA before transplantation. The most frequently reported adverse events were fatigue (in 38% of patients), headache (23%), and anemia (21%).ConclusionsAdministration of sofosbuvir and ribavirin before liver transplantation can prevent post-transplant HCV recurrence. ClinicalTrials.gov: NCT01559844
Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial
<p><b>Purpose</b></p>
<p>PERFORM is exploring the efficacy of terutroban
versus aspirin for secondary prevention in patients with a
history of ischemic stroke or transient ischemic attacks
(TIAs). The PERFORM Vascular Project will evaluate the
effect of terutroban on progression of atherosclerosis, as
assessed by change in carotid intima-media thickness
(CIMT) in a subgroup of patients.</p>
<p><b>Methods and results</b></p>
<p>The Vascular Project includes structural
(CIMT, carotid plaques) and functional (carotid
stiffness) vascular studies in all patients showing at least
one carotid plaque at entry. Expected mean follow-up is
36 months. Primary endpoint is rate of change of CIMT.
Secondary endpoints include emergent plaques and assessment
of carotid stiffness. 1,100 patients are required for
90% statistical power to detect treatment-related CIMT
difference of 0.025 mm. The first patient was randomized
in April 2006.</p>
<p><b>Conclusions</b></p>
<p>The PERFORM Vascular Project will investigate
terutroban’s effect on vascular structure and function in
patients with a history of ischemic stroke or TIAs.</p>
Mothers' accounts of their stillbirth experiences and of their subsequent relationships with their living infant:an interpretative phenomenological analysis
BACKGROUND: Due to contradictory findings regarding the effects of seeing and holding stillborn infants on women's worsening mental health symptoms, there is a lack of clear of guidance in stillbirth bereavement care. Although some current research examines this phenomenon we are still not certain of the meaning of such experiences to women and what effects there may be on her subsequent parenting. Thus the present study focuses on the meaning of the stillbirth experience to women and its influence on the subsequent pregnancy and subsequent parenting from the mothers' own experiences. METHODS: A purposive sample of six women who experienced a stillbirth during their first pregnancy and who then went on to give birth to a living child after a further pregnancy, took part in email interviews, providing rich and detailed experiential narratives about both the stillbirth itself, and their relationship with their living child. An Interpretive Phenomenological Analysis was carried out in order to focus on mothers making sense of such experiences. RESULTS: Analysis of written accounts led to the development of three overarching themes. In 'Broken Canopy', 'How This Happened' and 'Continuing Bonds', their accounts revealed an ongoing process where women accepted a new 'unsafe' view of the world, re-evaluated their view of self and others, and established relationships with both the deceased and the living infant. CONCLUSIONS: This study provided an insight into the stillbirth experience of mothers and its meaning to them with an existential focus. Typically the mother struggled with the contradictory process of accepting the existence of her deceased baby (this baby once lived) while being aware of the nonexistence (this baby). Meeting the dead baby was a crucial point at which the mother started processing her grief. The importance of individual differences in dealing with stressful situations was highlighted in terms of attachment strategies. Subsequent parenting experiences of mothers were very much influenced by their own previous experiences. Although some mothers managed to integrate this trauma into their life some remained very concerned and anxious about future and this anxiety then translated into their parenting experiences
Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/144684/1/ajt14752_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/144684/2/ajt14752.pd
Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein
The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and models the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. A TaqMan low-density array (TLDA) was used to characterise the expression of 380 genes associated with chemotherapy resistance in IGROVCDDP cells. Paclitaxel resistance in IGROVCDDP is mediated by gene and protein overexpression of P-glycoprotein and the protein is functionally active. Cisplatin resistance was not reversed by elacridar, confirming that cisplatin is not a P-glycoprotein substrate. Cisplatin resistance in IGROVCDDP is multifactorial and is mediated in part by the glutathione pathway and decreased accumulation of drug. Total cellular glutathione was not increased. However, the enzyme activity of GSR and GGT1 were up-regulated. The cellular localisation of copper transporter CTR1 changed from membrane associated in IGROV-1 to cytoplasmic in IGROVCDDP. This may mediate the previously reported accumulation defect. There was decreased expression of the sodium potassium pump (ATP1A), MRP1 and FBP which all have been previously associated with platinum accumulation defects in platinum-resistant cell lines. Cellular localisation of MRP1 was also altered in IGROVCDDP shifting basolaterally, compared to IGROV-1. BRCA1 was also up-regulated at the gene and protein level. The overexpression of P-glycoprotein in a resistant model developed with cisplatin is unusual. This demonstrates that P-glycoprotein can be up-regulated as a generalised stress response rather than as a specific response to a substrate. Mechanisms characterised in IGROVCDDP cells may be applicable to relapsed ovarian cancer patients treated with frontline platinum/taxane chemotherapy
High Quality Care and Ethical Pay-for-Performance: A Society of General Internal Medicine Policy Analysis
BACKGROUND: Pay-for-performance is proliferating, yet its impact on key stakeholders remains uncertain. OBJECTIVE: The Society of General Internal Medicine systematically evaluated ethical issues raised by performance-based physician compensation. RESULTS: We conclude that current arrangements are based on fundamentally acceptable ethical principles, but are guided by an incomplete understanding of health-care quality. Furthermore, their implementation without evidence of safety and efficacy is ethically precarious because of potential risks to stakeholders, especially vulnerable patients. CONCLUSION: We propose four major strategies to transition from risky pay-for-performance systems to ethical performance-based physician compensation and high quality care. These include implementing safeguards within current pay-for-performance systems, reaching consensus regarding the obligations of key stakeholders in improving health-care quality, developing valid and comprehensive measures of health-care quality, and utilizing a cautious evaluative approach in creating the next generation of compensation systems that reward genuine quality
Chapter 4 PREDICTING RESPONSES OF GEO-ECOLOGICAL CARBONATE REEF SYSTEMS TO CLIMATE CHANGE: A CONCEPTUAL MODEL AND REVIEW
oceanography, climate change, reefs, marine science, marine conservation, marine researc
- …